United State and Canada Biosimulation Industry is predicted to grow at a CAGR of 21.6% to reach US$8.7 Billion by 2032 | FMI Study

The favorable government policies in the United States, as well as growing healthcare expenditures due to the prevalence of chronic illnesses, are major drivers driving drug research and discovery in the United States and Canada. The Biosimulation Industry in the United States is expected to reach US$8.7 billion by 2032. With an estimated market size …